Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma.
NCT02814643 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma.
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 1, 2016
- Completion date
- January 24, 2017
- Enrollment
- 103 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.